CFGS
CSTL icon

Concourse Financial Group Securities’s Castle Biosciences CSTL Stock Holding History

Concourse Financial Group Securities’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,960
Closed -$185K – 435
2024
Q4 		$185K Buy
+6,960
New +$212K 0.01% 750
2020
Q3 		– Sell
-300
Closed -$13.3K – 2168
2020
Q2 		$11K Buy
+300
New +$10.3K ﹤0.01% 1457

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Concourse Financial Group Securities's CSTL Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 6,960 shares — an estimated $185K sold.

Concourse Financial Group Securities first reported a position in CSTL in Q2 2020 and held it in 2 quarters. The position peaked at $185K in Q4 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 6,960 Castle Biosciences shares in Q1 2025, an estimated $185K.
  • Concourse Financial Group Securities first reported a position in Castle Biosciences in Q2 2020 and held it in 2 quarters.
  • Concourse Financial Group Securities's Castle Biosciences position peaked at $185K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.